Camille L Bedrosian insider trades: Amylyx Pharmaceuticals (AMLX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Camille reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | AMLX | ↓ Sell | 10,028 | $32.40 | $325K | Direct | Sep 14, 2026 (4d) |
| Mar 2, 2026 | AMLX | ↓ Sell | 6,461 | $14.58 | $94K | Direct | Mar 4, 2026 (2d) |
| Dec 1, 2025 | AMLX | ↓ Sell | 6,580 | $14.35 | $94K | Direct | Dec 3, 2025 (2d) |
| Sep 30, 2025 | AMLX | ↓ Sell | 12,039 | $14.58 | $176K | Direct | Oct 2, 2025 (2d) |
| Mar 31, 2025 | AMLX | ↓ Sell | 12,425 | $3.47 | $43K | Direct | Apr 2, 2025 (2d) |
| Dec 2, 2024 | AMLX | ↓ Sell | 5,421 | $5.54 | $30K | Direct | Dec 3, 2024 (1d) |
| Sep 30, 2024 | AMLX | ↓ Sell | 11,442 | $3.20 | $37K | Direct | Oct 2, 2024 (2d) |
| Mar 1, 2023 | RARE | ↓ Sell | 3,881 | $45.25 | $176K | Direct | Mar 3, 2023 (2d) |
| Mar 1, 2022 | RARE | ↓ Sell | 2,821 | $66.62 | $188K | Direct | Mar 3, 2022 (2d) |
| Jan 30, 2022 | RARE | ↓ Sell | 1,657 | $66.30 | $110K | Direct | Feb 1, 2022 (2d) |
| Oct 14, 2021 | RARE | ↓ Sell | 359 | $81.14 | $29K | Direct | Oct 18, 2021 (4d) |
| Sep 2, 2021 | RARE | ↓ Sell | 5,000 | $100.11 | $501K | Direct | Sep 2, 2021 (0d) |
| May 6, 2021 | RARE | ↓ Sell | 364 | $113.67 | $41K | Direct | May 10, 2021 (4d) |
| Apr 15, 2021 | RARE | ↓ Sell | 5,000 | $109.09 | $545K | Direct | Apr 19, 2021 (4d) |
| Mar 1, 2021 | RARE | ↓ Sell | 4,543 | $138.18 | $628K | Direct | Mar 3, 2021 (2d) |
| Jan 30, 2021 | RARE | ↓ Sell | 2,243 | $140.36 | $315K | Direct | Feb 2, 2021 (3d) |
| Jan 15, 2021 | RARE | ↓ Sell | 25,000 | $139.18 | $3.5M | Direct | Jan 19, 2021 (4d) |
| Oct 14, 2020 | RARE | ↓ Sell | 262 | $88.00 | $23K | Direct | Oct 16, 2020 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AMLX insiders
Open-market trades in the last 12 months
About Camille L Bedrosian's insider trades
Camille L Bedrosian is Chief Medical Officer at Amylyx Pharmaceuticals (AMLX). Since Oct 14, 2020, Camille has reported no open-market purchases and 18 sales worth $6.8M on SEC Form 4. In the last 12 months: 3 sales ($513K).
Their filings also include grants and awards (28 filings), option exercises (5 filings), shares withheld for taxes (4 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AMLX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.